This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 71574 results found since Jan 2013.
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
Condition: Seasonal Allergic Rhinitis Interventions: Biological: LP-003 dose 1; Biological: LP-003 dose 2; Biological: Placebo Sponsor: Longbio Pharma Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome Interventions: Drug: NS-229; Drug: Placebo Sponsors: NS Pharma, Inc.; Nippon Shinyaku Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy Interventions: Drug: INZ-701; Drug: Control Arm (Conventional Therapy) Sponsor: Inozyme Pharma Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Conditions: Hepatic Impairment; Healthy Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; Veranex Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
Condition: Seasonal Allergic Rhinitis Interventions: Biological: LP-003 dose 1; Biological: LP-003 dose 2; Biological: Placebo Sponsor: Longbio Pharma Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome Interventions: Drug: NS-229; Drug: Placebo Sponsors: NS Pharma, Inc.; Nippon Shinyaku Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
Condition: Seasonal Allergic Rhinitis Interventions: Biological: LP-003 dose 1; Biological: LP-003 dose 2; Biological: Placebo Sponsor: Longbio Pharma Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome Interventions: Drug: NS-229; Drug: Placebo Sponsors: NS Pharma, Inc.; Nippon Shinyaku Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Conditions: Hepatic Impairment; Healthy Intervention: Drug: Obicetrapib Sponsors: NewAmsterdam Pharma; Veranex Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy Interventions: Drug: INZ-701; Drug: Control Arm (Conventional Therapy) Sponsor: Inozyme Pharma Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
LifeMD partners with pharma company for direct-to-consumer hormone therapy
Postmenopausal patients can get a prescription for ASCEND Therapeutics ' EstroGel by scheduling an appointment with a LifeMD provider through the pharma brand ' s website.
Source: mobihealthnews - September 21, 2023 Category: Information Technology Source Type: news
Premenstrual Disorders Tied to Earlier Natural Menopause
THURSDAY, Sept. 21, 2023 -- Premenstrual disorders (PMDs) are associated with a higher risk for early menopause, according to a study published online Sept. 19 in JAMA Network Open.
Yihui Yang, from the Karolinska Institutet in Stockholm, and...
Source: Drugs.com - Pharma News - September 21, 2023 Category: Pharmaceuticals Source Type: news
Women Less Likely to Get CPR for Cardiac Arrest in Public Place Than Men
THURSDAY, Sept. 21, 2023 -- Women are significantly less likely to receive bystander cardiopulmonary resuscitation (BCPR) than men when experiencing out-of-hospital cardiac arrest (OHCA) in a public location, according to a study presented at the...
Source: Drugs.com - Pharma News - September 21, 2023 Category: Pharmaceuticals Source Type: news
2006 to 2020 Saw Decrease in Death Following First Heart Attack
THURSDAY, Sept. 21, 2023 -- Death rates following a first heart attack decreased for those without diabetes or with type 2 diabetes (T2D), but not for those with type 1 diabetes (T1D), according to a study scheduled to be presented at the annual...
Source: Drugs.com - Pharma News - September 21, 2023 Category: Pharmaceuticals Source Type: news
More Than 10 Million U.S. Adults Live in Counties Without Psychiatrists, Broadband
THURSDAY, Sept. 21, 2023 -- More than 10 million people lived in U.S. counties without psychiatrists and broadband coverage in 2020, according to a research letter published online Sept. 14 in JAMA Network Open.
Tarun Ramesh, from Harvard Medical...
Source: Drugs.com - Pharma News - September 21, 2023 Category: Pharmaceuticals Source Type: news
